1-6 of 6
Eva Nordström
Close
Sort by
Journal Articles

Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1

Sara Bringhen, Peter M. Voorhees, MD, Torben Plesner, MD DSc, Ulf-Henrik Mellqvist, MD PhD, Brandi Reeves, MD, Pieter Sonneveld, Catriona Byrne, RN, Eva Nordström, MSc, Johan Harmenberg, MD PhD, Jakob Obermüller, MSc, Paul G. Richardson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1839.
https://doi.org/10.1182/blood-2019-124828
Published: 2019
Journal Articles

First Report on Overall Survival (OS) and Improved Progression Free Survival (PFS) in a Completed Phase 2a Study of Melflufen in Advanced Relapsed Refractory Multiple Myeloma (RRMM)

Paul G Richardson, MD, Sara Bringhen, MD, Peter M. Voorhees, MD, Torben Plesner, MD, Claudia Paba-Prada, MD, Ulf-Henrik Mellqvist, MD, Jeffrey A Zonder, MD, Brandi Reeves, MD, Antonio Palumbo, MD, Catriona Byrne, RN, Johan Harmenberg, MD PhD, Eva Nordstrom, MSc, MBA, Hanan Zubair, MSc, Jakob Lindberg, MD PhD, Pieter Sonneveld, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3150.
https://doi.org/10.1182/blood.V130.Suppl_1.3150.3150
Published: 2017
Journal Articles

Melflufen Therapy for Relapsed Refractory Multiple Myeloma (RRMM) Patients Refractory to Daratumumab and/or Pomalidomide: A Report on Early Efficacy

Maria-Victoria Mateos, MD, Joan Bladé, MD PhD, Alessandra Larocca, Albert Oriol, MD, Paula Rodriguez, MD, Adrián Alegre, MD, Michele Cavo, MD, Jan S Moreb, MD, Agne Paner, MD, Nashat Gabrail, MD, Kathleen G. Halka, MD, Hani Hassoun, MD, Christopher Maisel, MD, Amitabha Mazumder, MD, Jeffrey A Zonder, MD, Enrique M Ocio, MD, Catriona Byrne, RN, Johan Harmenberg, MD PhD, Sara Thuresson, MSc, Eva Nordstrom, MSc, MBA, Jakob Lindberg, MD PhD, Paul G Richardson, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1841.
https://doi.org/10.1182/blood.V130.Suppl_1.1841.1841
Published: 2017
Journal Articles

Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival

Peter M. Voorhees, MD, Valeria Magarotto, MD, Pieter Sonneveld, MD PhD, Torben Plesner, MD, Ulf-Henrik Mellqvist, MD PhD, Claudia E. Paba-Prada, MD, Catriona Byrne, RN, Johan Harmenberg, MDPhD, Eva Nordstrom, MSc,MBA, Antonio Palumbo, MD, Paul Richardson, MD
Journal: Blood
Blood (2015) 126 (23): 3029.
https://doi.org/10.1182/blood.V126.23.3029.3029
Published: 2015
Journal Articles

A Novel Alkylating Agent Melphalan Flufenamide Ethyl Ester Induces an Irreversible DNA Damage in Multiple Myeloma Cells

Arghya Ray, PhD, Durgadevi Ravillah, PhD, Deepika Sharma Das, PhD, Yan Song, PhD, Eva Nordström, Jakob Lindberg, Paul G. Richardson, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2014) 124 (21): 2086.
https://doi.org/10.1182/blood.V124.21.2086.2086
Published: 2014
Journal Articles

Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM)

Claudia Paba-Prada, MD, Antonio Palumbo, MD, Ulf-Henrik Mellqvist, MD PhD, Peter M Voorhees, MD, Torben Plesner, MD, Pieter Sonneveld, MD, Catriona Byrne, RN, Johan Harmenberg, MDPhD, Eva Nordstrom, MSc,MBA, Paul G. Richardson
Journal: Blood
Blood (2014) 124 (21): 2123.
https://doi.org/10.1182/blood.V124.21.2123.2123
Published: 2014